Buddha Gurung

Buddha Gurung has a diverse and extensive work experience. Buddha is currently the Director of Cell Engineering at Century Therapeutics, Inc, a position they have held since March 2022. Prior to this role, they worked at Century Therapeutics as an Associate Director of Cell Engineering from January 2020 to March 2022, and as a Group Leader of Research Cell Therapy from January 2019 to January 2020. Before joining Century Therapeutics, Buddha worked at The Janssen Pharmaceutical Companies of Johnson & Johnson as a Scientist from September 2016 to December 2018. In this role, they played a crucial part in the development and advancement of the allogeneic CAR T platform targeting hematological malignancies, leading gene-editing efforts and designing and conducting experiments to validate the potency and efficacy of CAR T cell therapy products. Prior to that, Buddha worked as a Research Associate at the University of Pennsylvania from January 2013 to September 2016, where they focused on immunotherapy for targeting neuroendocrine tumors and evaluating the cytotoxicity of CAR-T cells. Buddha began their career as a Postdoctoral Researcher at the University of Pennsylvania School of Medicine from January 2008 to December 2012, conducting research on the Hedgehog signaling pathway and its role in MEN1 tumor syndrome.

Buddha Gurung earned a Bachelor of Science degree in Biochemistry and Molecular Biology from Oklahoma State University from 1995 to 2001. Buddha then pursued a Doctor of Philosophy in Biochemistry and Molecular Biology from Oklahoma State University, completing it from 2001 to 2007.